Hopp til hovedinnhold

Hypertrofisk kardiomyopati

Sist oppdatert: Sist revidert:
Sist revidert av:
Definisjon:
Hypertrofisk kardiomyopati er en genetisk forstyrrelse karakterisert ved venstre ventrikkelhypertrofi uten påvisbar årsak til hypertrofi
Forekomst:
Det er den vanligste genetiske hjertesykdommen, og den hyppigste årsaken til plutselig hjertedød blant unge mennesker og idrettsutøvere
Symptomer:
I mange år asymptomatisk. Funksjonsdyspné og brystsmerter er de hyppigste symptomene
Funn:
Ofte få kliniske funn. Iktus kan være utrykket. Ut i forløpet kan høres en midt-sensystolisk ejeksjonsbilyd langs venstre sternalrand
Diagnostikk:
Ekkokardiografi avdekker som regel diagnosen. EKG er unormalt. Ev.MR. Ev. myokardbiopsi
Behandling:
Aktuelle behandlinger er medikamenter, pacemaker, intern defibrillator, radioablasjon, kirurgi, transplantasjon
  1. Elliot PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2733-79. pmid:25173338 PubMed  
  2. Spirito P, Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006; 332: 1251-5. British Medical Journal  
  3. Maron BJ, Olivotto I, Maron MS. The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? Eur Heart J. 2006 Aug;27(16):1895-7. PMID: 16818455 PubMed  
  4. Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015; 65:1249-54. PMID: 25814232 PubMed  
  5. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol. 2008;19:104-110. PMID: 17916152 PubMed  
  6. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-91. PubMed  
  7. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81: 1339-44. PubMed  
  8. Maron BJ, Niimura H, Casey SA, et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001; 38: 315-21. PubMed  
  9. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349: 1027-35. New England Journal of Medicine  
  10. Wu G, Liu J, Wang S, et al. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. Heart 2021. pmid:33361398 PubMed  
  11. Maron BJ. Hypertrophic cardiomyopathy. A systematic review. JAMA 2002; 287: 1308-20. Journal of the American Medical Association  
  12. Chen AS, Bent RE, Wheeler M, et al. Large Q and S waves in lead III on the electrocardiogram distinguish patients with hypertrophic cardiomyopathy from athletes. Heart 2018. doi:10.1136/heartjnl-2017-312647 DOI  
  13. Gandjbakhch E, Gackowsi A, Tezenas du Montcel, et al. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. Eur Haert J 2010;31:1599-607. PubMed  
  14. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020. pmid:33215938 PubMed  
  15. Maron BJ.The 2009 International Hypertrophic Cardiomyopathy Summit . Am J Cardiol 2010; 105: 1164-8. PubMed  
  16. Moon JCC, McKenna WJ, McCrohon JA et al. Towards clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-67. PubMed  
  17. Carsten R, Norbert MW, Michael JH, Susan AC, Prasad P, Neeta P, et al. Utility of Cardiac Magnetic Resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112: 855-61. Circulation  
  18. Leonardo S, Rainieri C, De Ferrari GM, et al. Usefulness of cardiac magnetic resonance in assessing the risk of ventericual arrhythmias and of sudden death in patients with hypertrophic cardiomyopathy. Eur Heart J 2009; 30: 2003-10. European Heart Journal  
  19. Sen-Chowdry S, McKenna WJ. Non-invasive risk-stratification in hypertrophic cardiomyopathy: don`t throw out the baby with the bathwater. Eur Heart J 2008; 29: 1600-02.
  20. O'Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99:534-541. PubMed  
  21. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary. Circulation 2011; 124: 2761-96. Circulation  
  22. Michels M, Soliman OI,Ten Cate FJ, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J 2009; 30: 2953-8. European Heart Journal  
  23. Christiaans I, Birnie E, Bonsel GJ, et al. Manifest disease, risk factors for sudden death, and large cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. Eur Heart J 2011; 32: 1161-70. European Heart Journal  
  24. Corrado D, Pelliccia A, Bjørnstad H, Vanhees L. Preparticipation screening of young competitive athletes for prevention of sudden death: proposal of a common European protocol. Eur Heart J 2005; 26: 516-24. European Heart Journal  
  25. Corrado D, Basso C, Pavei A, et al. Trends in sudden cardiovascular death in young competetive athletes after implementation of a preparticipation screening program. JAMA 2006; 296: 1593-601. Journal of the American Medical Association  
  26. Bille K, Figueiras D, Schamasch P, et al. Sudden cardiac death in athletes: the Lausanne recommendations. Eur J Cardiovasc Prev Rehabil 2006; 13: 859-75. PubMed  
  27. Mukherjee M, Abraham T. Hypertrophic cardiomyopathy. BMJ Best Practice, last updated Sep 17, 2014.
  28. Gati S, Sharma S. Exercise prescription in individuals with hypertrophic cardiomyopathy: what clinicians need to know. Heart 2022. pmid:35197306 PubMed  
  29. Sweeting J, Ingles J, Timperio A, et al. Physical activity in hypertrophic cardiomyopathy: prevalence of inavtivity and preceived barriers. Open Heart 2016. doi:10.1136/openhrt-2016-000484 DOI  
  30. Lampert R, Ackerman MJ, Marino BS, et al. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol 2023. pmid:37195701 PubMed  
  31. Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2021; 78: 2505-17. pmid:34915981 PubMed  
  32. Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2021;397:2467-75. PMID: 34004177 PubMed  
  33. Nishimura RA, Holmes DR Jr. Hypertrophic obstructive cardiomyopathy. N Engl J Med 2004; 350: 1320-7. New England Journal of Medicine  
  34. Thaman R, Varnava A, Hamid MS, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart 2003; 89: 752-56. PubMed  
  35. Autore C, Conte MR, Piccininno M, Bernabò P, Bonfiglio G, Bruzzi P, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40: 1864-9. PubMed  
  36. Cui H, Schaff HV, Wang S, et al. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2022; 79: 1647-55. pmid:35483751 PubMed  
  37. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000; 36: 852-55. PubMed  
  38. LIebregts M, Faber L, Jensen MK, et al. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy. JACC Cardiovasc Interv. 2017; 10: 1134-43. pmid:28595881 PubMed  
  39. Batzner A, Pfeiffer B, Neugebauer A, et al. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol 2018; 72: 3087-94. pmid:30545446 PubMed  
  40. Maron BJ, Yacoub M, Dearani JA. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back to European patients. Eur Heart J 2011; 32:1055-8. European Heart Journal  
  41. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003; 24: 1965-91. European Heart Journal  
  42. Pelliccia A, Corrado D, Bjornstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005; 26: 1422-45. European Heart Journal  
  43. Elliott PM, Gimeno Blanes JR, Mahon NG, McKenna WJ. Relation between the severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420-24. PubMed  
  44. Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J 2010; 31: 1551-3. European Heart Journal  
  • Ingard Løge, spesialist allmennmedisin, redaktør NEL

Tidligere fagmedarbeidere

  • Hans H Bjørnstad, dr. med., spesialist i hjertesykdommer, overlege Sykehuset Telemark, medisinsk avdeling, Rjukan
  • Åsne B Bjørnstad, lege i spesialisering, medisinsk avdeling, Diakonissehjemmets sykehus, Haraldsplass, Bergen